R1 RCM (NASDAQ:RCM) Given “Outperform” Rating at Robert W. Baird

Robert W. Baird reaffirmed their outperform rating on shares of R1 RCM (NASDAQ:RCM) in a report issued on Tuesday, Benzinga reports. Robert W. Baird currently has a $18.00 price objective on the healthcare provider’s stock.

A number of other equities analysts have also commented on the stock. Truist Financial reissued a hold rating and issued a $16.00 price target on shares of R1 RCM in a research report on Monday, April 1st. Citigroup raised shares of R1 RCM from a neutral rating to a buy rating and set a $16.00 price target on the stock in a research report on Wednesday, March 20th. KeyCorp restated a sector weight rating on shares of R1 RCM in a research note on Wednesday, April 10th. Canaccord Genuity Group lowered their price objective on shares of R1 RCM from $16.00 to $15.00 and set a buy rating on the stock in a research note on Thursday, May 9th. Finally, Guggenheim lowered their price objective on shares of R1 RCM from $17.00 to $15.00 and set a buy rating on the stock in a research note on Friday, April 5th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $16.00.

R1 RCM Price Performance

Shares of RCM opened at $11.13 on Tuesday. The firm has a market cap of $4.69 billion, a PE ratio of -139.13 and a beta of 0.85. The firm’s 50 day moving average price is $12.39 and its 200 day moving average price is $11.89. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 1.79. R1 RCM has a twelve month low of $8.87 and a twelve month high of $18.70.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings data on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The business had revenue of $603.90 million for the quarter, compared to the consensus estimate of $612.88 million. The firm’s revenue was up 10.7% compared to the same quarter last year. As a group, research analysts expect that R1 RCM will post -0.17 EPS for the current fiscal year.

Institutional Investors Weigh In On R1 RCM

A number of institutional investors have recently bought and sold shares of RCM. Neo Ivy Capital Management acquired a new stake in shares of R1 RCM in the 3rd quarter valued at $269,000. abrdn plc acquired a new stake in shares of R1 RCM in the 4th quarter valued at $3,772,000. First Light Asset Management LLC acquired a new stake in shares of R1 RCM in the 4th quarter valued at $8,625,000. Aigen Investment Management LP acquired a new stake in shares of R1 RCM in the 4th quarter valued at $758,000. Finally, Voss Capital LLC boosted its stake in shares of R1 RCM by 553.9% in the 4th quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock valued at $75,311,000 after purchasing an additional 6,035,340 shares in the last quarter. Institutional investors and hedge funds own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.